Literature DB >> 3679917

Treatment of advanced head and neck cancer with concomitant radiation and chemotherapy.

A K Murthy1, S G Taylor, J Showel, D D Caldarelli, J C Hutchinson, L D Holinger, T R Witt, S Hoover.   

Abstract

Forty-four patients with predominantly inoperable or recurrent head and neck cancers were treated with combined chemotherapy (CT) and radiation therapy (RT) in a Phase I/II study. CT and RT were combined in a concomitant fashion to take advantage of radiosensitizing properties of the chemotherapeutic agents. Each treatment cycle consisted of cisplatin 60 mg/M2 on day 1, 5-FU infusion at a dose of 800 mg/M2 per day continuously for 5 days and RT at 200 cGy per day, days 1 through 5. The treatment cycle was repeated every 2 weeks for 7 cycles in patients treated curatively and for 2 to 6 cycles in patients treated palliatively due to prior radiation therapy or the presence of metastatic disease. Regional control was achieved in 98% of the patients. Regional control has persisted in 87% of the patients treated curatively with a minimum follow-up of 24 months. Distant failure occurred in 23% of this group. Actuarial survival of 2 years for the curative group is 66%. Concomitant combination of radiation with radiation potentiating chemotherapeutic agents shows promise of increase in local control.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3679917     DOI: 10.1016/0360-3016(87)90345-2

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  2 in total

1.  Targeted infusions of supradose Cisplatin with systemic neutralization for carcinomas invading the temporal bone.

Authors:  K T Robbins; P K Pelliteri; D Vicario; C W Kerber; J H Robertson; C Hanchett; S B Howell
Journal:  Skull Base Surg       Date:  1996

2.  Selective intraarterial chemoradiation therapy for oropharyngeal carcinoma with high-dose cisplatin.

Authors:  Ryota Nishio; Kazuhiro Saito; Hiroyuki Ito; Tomoyuki Yoshida; Koichi Kitamura; Akira Shimizu; Naoto Kanesaka; Ryuji Mikami; Daisuke Hasegawa; Mamoru Suzuki; Koichi Tokuuye
Journal:  Jpn J Radiol       Date:  2011-09-17       Impact factor: 2.374

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.